Omecamtiv mecarbil (INN) previously codenamed CK-1827452 is a cardiac specific myosin activator. It is clinically tested for its role in the treatment of left ventricular systolic heart failure. Systolic heart failure is characterised as a decreased cardiac output (<40% ejection fraction) due to decreased stroke volume resulting in the inability to meet the metabolic demands of the body.
This page contains content from the copyrighted Wikipedia article "Omecamtiv mecarbil"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
